8 results about "OralSuspension" patented technology

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.

The present invention provides a liquid composition comprising effective amount of Hydroxyurea for oral administration. The invention further discloses liquid formulation in form of ready to use oral suspension which remains stable at room temperature at the time of dispensing, storage and even after reopening of the container comprising the suspension. Also provided is a method of preparing the formulation and treating sickle cell anemia in pediatric patients.

The invention belongs to the technical field of pharmaceutical preparations, and relates to an anhydroicaritin nanocrystal oral suspension and a preparation method thereof. The oral suspension contains anhydroicaritin nanocrystals, a suspending aid, a surfactant, a buffer salt system and other pharmaceutically acceptable auxiliary materials. By optimizing the surfactant system and the pH range, the stability of the anhydroicaritin is effectively improved. The problem of long-term stability of a nanocrystalline oral suspension preparation prepared from anhydroicaritin is solved. According to the prescription, the dissolution speed of the medicine is increased, the bioavailability is improved, and the preparation method is easy to operate, stable in process and suitable for industrial production.

This invention discloses an oral suspension of an anti-tuberculosis drug and its preparation method. The oral suspension contains an anti-tuberculosis drug, a suspending agent, a surfactant, an antibacterial agent, an antioxidant, a flavoring agent, and a pH adjuster. It has technical advantages such as stable physical and chemical properties, uniform content, and easy long-term storage.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to anhydroicaritin nanocrystalline oral suspension and a preparation method thereof. The oral suspension disclosed by the invention contains anhydroicaritin nanocrystals, a space protecting agent, a surfactant, a preservative, a pH regulator and other pharmaceutically acceptable auxiliary materials. Compared with the prior art, the problem that the stability is poor after the anhydroicaritin is prepared into the nanocrystal is solved; particle size distribution is uniform, and aggregation and layering phenomena are avoided; related substances are controllable, the safety is higher, the taste is good, the dosage can be accurately divided according to the body weight, and children, old people and patients with dysphagia can take the medicine conveniently. The oral suspension is simple in preparation method and suitable for industrial production.

This invention discloses a perampanel oral suspension and its preparation method. The preparation method of this invention includes the following steps: S1, adding microcrystalline cellulose sodium carboxymethyl cellulose co-treatment material to water for homogenization to obtain a first dispersion; S2, adding sorbitol, an antibacterial agent, and a pH adjuster to the first dispersion to obtain a second dispersion; S3, pulverizing perampanel and sieving it to control the particle size D. 90 The sample size is 10–15 μm; S4, the perampanel obtained in step S3 is subjected to antistatic treatment; S5, the perampanel treated in step S4, defoamer, and polyoxyethylene hydrogenated castor oil are added to the second dispersion to obtain the third dispersion; S6, water is added to the third dispersion to bring it to a final volume, and homogenization is performed to obtain the perampanel oral suspension. This method can significantly improve the dissolution rate, long-term stability, and control level of drug-related substances at day 0, and improve the uniformity of content.

This document discloses rivaroxaban tablets for oral suspension formulation for oral administration. Also disclosed is a method for preparing rivaroxaban tablets for oral suspension and a method of treating diseases.

A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.